Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Calidi Biotherapeutics announced its second quarter 2026 financial results, highlighting positive FDA pre-IND feedback on its lead candidate CLD-401, progress in its RedTail oncolytic virus platform, presentation of preclinical data for CLD-501 at ASCO 2026, board expansion with industry veteran Corsee Sanders, and a 48% reduction in general and ad…